About Skyviews Life Science
Skyviews Life Science is a venture capital firm founded in 2018. It is primarily based out of Grandvaux, France. As of Dec 2024, Skyviews Life Science has invested in 19 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Food and Agriculture Tech. Most recently it participated in the $***** Series A round of One bio Overall, Skyviews Life Science portfolio has seen 4 IPOs including key companies like Siemens Healthineers, COMPASS Pathways and Beyond Meat. A lot of funds co-invest with Skyviews Life Science, with names like Leaps by Bayer sharing a substantial percentage of its portfolio. Skyviews Life Science has team of 7 people including 5 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series A & 2 more
Portfolio IPOs
Portfolio Soonicorns
Skyviews Life Science's List of Top Investments
Skyviews Life Science has a portfolio of 19 companies. Their most notable investments are in Mirai Foods and COMPASS Pathways.Their portfolio spans across United States, United Kingdom, Switzerland and 4 more locations. They have invested in Life Sciences, High Tech, Food and Agriculture Tech and 6 other sectors, across stages such as Series B, Series A and 2 more. Here is the list of top investments by Skyviews Life Science:Provider of medical imaging laboratory diagnostics and clinical digital solutions. The business develops and manufactures technology for cancer care, point-of-care testing, and healthcare information systems. Offerings include automation tools, robotics, and software for clinical decision support. The portfolio supports diagnostic and therapeutic workflows across various medical fields.
Key facts about Siemens Healthineers
- Founded Year: 2017
- Location: Forchheim (Germany)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Employee Count: 69,730 as on Sep 30, 2025
- Investors: Qatar Investment Authority, Skyviews Life Science and 3 Others
- Latest Funding Round: Grant (prize money), Apr 01, 2023, $*****
- Highlight: Public
Developer of gene editing technologies for improved tropical crop production. The company focuses on improving crops to be tastier and hardier. It aims to make crops less reliant on pesticides and more resilient to climate change. The company’s technology supports farmers, equipping them against climate change. It helps them to increase their yields.
Key facts about Tropic Biosciences
Developer of therapies for treating mental disorders. The company is developing psilocybin therapy (a psychoactive medicine) for the treatment of resistant depression which acts as a partial agonist for several serotonin receptors.
Key facts about COMPASS Pathways
- Founded Year: 2016
- Location: London (United Kingdom)
- Stage: Public
- Total Funding till date: $109M
- Employee Count: 274 as on Jul 31, 2026
- Investors: Perceptive Advisors, Armistice Capital and 20 Others
- Latest Funding Round: Post IPO, Aug 16, 2023, $*****
- Highlight: Public
4. Aleph Farms
Develops lab-cultured meat products using beef cells. Its product offerings include ground meat, beef burger patties, steaks, etc. The company uses proprietary 3D bioprinting technologies by using fat cells, support cells, muscle cells, and blood vessel cells to develop tissues and further into meat products. Claims that the process takes 3 weeks to develop the meat in bioreactors.
Key facts about Aleph Farms
- Founded Year: 2017
- Location: Ashdod (Israel)
- Stage: Series B
- Total Funding till date: $118M
- Employee Count: 57 as on Jul 31, 2026
- Investors: La Maison Partners, Lansdowne Partners and 55 Others
- Latest Funding Round: Series B, Jun 07, 2023, $*****
- Highlight: Editors' Pick
5. Cellares
Manufacturer of a medical device for cell-based therapy. The company offers Cell Shuttle integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers true walk-away, end-to-end automation. It also, offers software suite for cell therapy modalities.
Key facts about Cellares
- Founded Year: 2019
- Location: San Francisco (United States)
- Stage: Series D
- Total Funding till date: $682M
- Employee Count: 334 as on Jul 31, 2026
- Investors: T. Rowe Price, Baillie Gifford and 17 Others
- Latest Funding Round: Series D, Jun 15, 2026, $*****
- Highlight: Editors' Pick
Skyviews Life Science's Year-on-Year Investment Trends
Skyviews Life Science has invested in 19 companies over the last 6 years, with an average of 0 new investment annually in the last 5 years. Its most recent first time investment was in One bio and most recent follow-on round was in Vedanta Biosciences.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 1 | 1 | 2 |
2023 | 0 | 1 | 1 |
2022 | 1 | 1 | 2 |
2021 | 5 | 0 | 5 |
2020 | 3 | 0 | 3 |
Skyviews Life Science's Investments by Stage
Skyviews Life Science has made 6 investments in Series B stage with an average round size of $57.4M, 2 investments in Series A stage with an average round size of $27M, 1 investment in Seed stage with an average round size of $2.15M and 1 investment in Series D stage with an average round size of $68M.Stage of entry | No. of Investments |
|---|---|
Series B | 6 |
Series A | 2 |
Seed | 1 |
Series D | 1 |
Note: We have considered here, only first round of investments
Skyviews Life Science's Investments by Sector
Skyviews Life Science has a diverse portfolio, with companies operating in the Life Sciences, Food and Agriculture Tech, Sustainability Tech, Consumer and Food and Agriculture. Notably, it has invested in 15 Tech companies, 13 Enterprise (B2B) companies, 4 Consumer (B2C) companies and at least 3 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 6 |
Food and Agriculture Tech | 2 |
Sustainability Tech | 2 |
Consumer | 1 |
Food and Agriculture | 1 |
Others | 3 |
Note: We have considered here, only first round of investments
Skyviews Life Science's Investments by Geography
Skyviews Life Science has made most investments in United States (4), followed by Switzerland where it has made 2 investments.Country | No. of Investments |
|---|---|
United States | 4 |
Switzerland | 2 |
United Kingdom | 2 |
France | 1 |
Israel | 1 |
Note: We have considered here, only first round of investments
Skyviews Life Science's recent investments
Skyviews Life Science has not made any investment in 2026 so far.Here are the most recent investments by Skyviews Life Science:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Dec 12, 2024 | United States | Series A | 4373 | [+7] | |
Feb 23, 2024 | United States | Series E | 1260 | ||
Mar 01, 2023 | United States | Series E | 9877 | [+15] | |
Oct 04, 2022 | Switzerland | Series A | 9682 | ||
Jul 06, 2022 | United Kingdom | Series C | 5889 | [+4] |
IPOs and Publicly Listed companies in Skyviews Life Science's Portfolio
4 of Skyviews Life Science's portfolio companies have become public. MaaT Pharma got listed on the Euronext Exchange (Euronext), in Nov 2021 at marketcap of $149M and COMPASS Pathways got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $592M.Here are Skyviews Life Science's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Nov 08, 2021 | Dec 01, 2020 | Series B | 1417 | |
Sep 18, 2020 | Apr 27, 2020 | Series B | 8480 | |
May 02, 2019 | - | - | 3902 | |
Mar 16, 2018 | - | - | 9408 |
Team profile of Skyviews Life Science
Skyviews Life Science has a team of 7 members including 5 Partners and 1 Principal located in Switzerland and United Kingdom. Skyviews Life Science's team does not sit on the board of any company as of now.Here is a list of all team members in Skyviews Life Science:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Lausanne | - | ||
Partner | London | - | - | |
Partner | Switzerland | - | - | |
Partner | Lausanne | - | - | |
Partner | London | - | ||
Principal | - | - | - |
Co-investors of Skyviews Life Science
Over the past 6 years, 141 investors have co-invested in Skyviews Life Science's portfolio companies. This includes funds and angels.
- Invested before Skyviews Life Science: Symbiosis, Seventure Partners and 46 others have invested in rounds before Skyviews Life Science. There are 2 companies where Symbiosis has invested before Skyviews Life Science and 2 companies where Seventure Partners has invested before Skyviews Life Science.
- Top Co-investors of Skyviews Life Science: 38 investors entered a company along with Skyviews Life Science. These include investors like Leaps by Bayer (2 companies).
- Invested after Skyviews Life Science: A total of 55 investors have invested in Skyviews Life Science's portfolio after their investments. Top Investors include Blue Horizon (1 company), ADQ (1 company) and Bloom8 (1 company).
Recent News related to Skyviews Life Science
•
•
One Bio Raises $27M to Advance Short-Chain Fiber Ingredients for GLP-1 Friendly FoodsThe Spoon•Dec 12, 2024•One bio, Alpha Edison, Leaps by Bayer, E12 Ventures and 8 others
•
Vedanta Biosciences Raises $106.5M in FundingFinSMEs•Apr 25, 2023•Vedanta Biosciences, AXA Investment Managers, AMR Action Fund, Gates and 14 others
•
Volumina Medical wins notable new investorsStartupticker•Oct 04, 2022•Volumina Medical, Clinique La Prairie, Skyviews Life Science
•
Tropic Biosciences Raises $35M For Gene-Editing & RNAi Platform Aimed at Developing Tropical CropsThe Spoon•Jul 06, 2022•Tropic Biosciences, Blue Horizon, ADQ, Bloom8 and 4 others
•
BCD Bioscience, a Precision Prebiotic Fiber Company, Raises $12M In Series A Funding to Develop Lead ProductsBusiness Wire•Apr 14, 2022•One bio, Acre Venture Partners, Seventure Partners, iSelect Fund and 3 others
•
Vedanta Biosciences Completes $68 Million Series D FinancingBusiness Wire•Jul 21, 2021•Vedanta Biosciences, Magnetar, Verition Fund Management, Fosun Pharmaceutical and 10 others
•
Aleph Farms’ $105 Million Series B FundingGlobal Legal Chronicle•Jul 14, 2021•Aleph Farms, DisruptED, Skyviews Life Science, Thai Union Group and 8 others
•
Cell therapy manufacturing tech startup Cellares raises $82 millionReuters•May 05, 2021•Cellares, Decheng Capital, Skyviews Life Science, 8VC and 1 other
•
Mirai Foods’ CEO says cell-based burger scalability is “unlimited” following US$4.5M seed financingFoodIngredientsFirst•Mar 25, 2021•Mirai Foods, FRIBA Investment, Skyviews Life Science, Paulig
